#0217

Febuxostat facilitates neovasculogenesis in chronic kidney disease through xanthine oxidase signaling pathways

C. Chiang¹, T. Chang²

¹Kaohsiung Veterans General Hospital, Division of Urology, Department of Surgery, Kaohsiung, Taiwan
²National Yang Ming Chiao Tung University, Department and Institute of Pharmacology, School of Medicine, Taipei, Taiwan

Introduction:

The accumulation of uremic toxins in circulation leads to cardiovascular diseases that result from chronic kidney disease (CKD). This study aimed to investigate febuxostat, a potent xanthine oxidase inhibitor, for its potential effects on the mechanisms of neovasculogenesis in a mouse model of CKD.

Material and methods:

CKD mice were generated using a 5/6 subtotal nephrectomy and orally administered with febuxostat. We compared with pre-OP and post-OP reactive oxygen species (ROS), renal function, urinary albumin-to-creatinine ratios, and renal inflammatory proteins.

Results:

In the CKD mice, febuxostat reduced systemic ROS and preserved kidney function, as evidenced by the reduced levels of serum blood urea nitrogen, creatinine, urinary albumin-to-creatinine ratios, and renal inflammatory proteins. In addition, febuxostat improved neovasculogenesis in an aortic ring assay, a Matrigel plug assay, and a wound healing assay in the CKD mice.